$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[국내논문] 구제역의 병리기전 및 진단, 예방백신 개발
Pathogenesis, Dianosis, and Prophylactic Vaccine Development for Foot-and-Mouth Disease 원문보기

한국응용생명화학회지 = Journal of the Korean Society for Applied Biological Chemistry, v.48 no.4, 2005년, pp.301 - 310  

문선화 (성균관대학교 유전공학과) ,  양주성 (성균관대학교 유전공학과)

초록
AI-Helper 아이콘AI-Helper

구제역(Foot-and-Mouth Disease: FMD)이란 소, 돼지, 양, 염소 등의 cloven-hoofed 동물에서 나타나는 바이러스성 질병으로 입, 코, 유두, 발굽 등에 수포가 형성되는 것이 특징이다. 일곱 가지 혈청형(O, A, C, Asia1, SAT1, SAT2 and SAT3)으로 분류되는 구제역바이러스(Foot-and-Mouth Disease Virus: FMDV)는 single stranded positive RNA virus로 nonenveloped capsid virus이다. Viral genome은 8.2 Kb로 하나의 ORF인 polyprotein으로 되어있으며, 크게 capsid protein coding region인 P1, replication related protein coding region인 P2, RNA dependent RNA polymerase coding region인 P3로 구성된다. FMDV는 respiratory tract의 pharynx epithelial cell에 감염되며, lung epithelial cell에서 replication을 한다. 구제역바이러스는 감염율은 높지만 낮은 치사율을 가진다. 2002년 한국에서 구제역이 발병하여 많은 경제적 손실을 입었다. FMDV의 감염을 조절할 수 있는 조절방법이 없는 실정이며, 현재 많은 나라에서는 구제역바이러스의 감염을 막을 수 있는 효과적인 방법을 연구하고 있다. 본 보고서에서는 FMD에 대한 보다 효과적인 예방법인 DNA vaccine, edible vaccine, peptide vaccine에 대해 고찰하였다.

Abstract AI-Helper 아이콘AI-Helper

Foot-and-mouth disease (FMD) is a highly contagious disease of mammals and has a great potential for causing severe economic loss in susceptible cloven-hoofed animals, such as cattle, pigs, sheep, goats and buffalo. FMDV, a member of the Aphthovirus genus in the Picornaviridae family, is a non-envel...

주제어

AI 본문요약
AI-Helper 아이콘 AI-Helper

* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.

문제 정의

  • 따라서 이 논문에서는 FMDV에 관련된 여러 논문을 고찰함으로써 FMDV pathogenesis와 diagnosis를 소개하고 다양한 치료법과 예방법을 살펴보고 치료와 예방가능성에 대해 고찰하였다.
  • 따라서 FMD에 대한 치료 및 그 예방에 관한 연구가 그 역사만큼이나 계속해서 활발히 진행되고 있으며, 그에 따라 여러 측면에서의 다양한 전략이 개발, 보고되어 있다. 이 section에서는 이미 살펴본 pathogenesis와 genome structure의 이해를 바탕으로 현재 보고된 다양한 therapeutic protection strategies를 DNA vaccine, Edible vaccine 과 기타 다른 전략 등으로 나누어 고찰 해보고자 한다.

가설 설정

  • 이러한 RGD sequence의 host cellular receptor로서 알려진 것은 avp6, avpi, av(33의 integrin과 highly acidic materials인 HS(heparan sulfete) 등이 있다.17) Receptor] attachment된 FMDV는 receptor- mediate endocytosis를 통하여 세포질 내에 endosome을 형성한다. Endosome 내부의 pH가 떨어짐에 따라 viral capsid protein 중 하나인 VP4가 uncoating 되고, 그러한 conformational change 는 곧 viral genome을 cytosol내로 release 되도록 유도한다.
  • 2~8일이 지나면 혀, 잇몸, 유두, 발굽 등에서 secondary vesicle이 형성되며 이에 따른 임상증상을 일으킨다. 22)Virus의배출은 임상증상이 일어나기 약 24시간 전에 시작하여 수일 간지 속된다. 감염동물의 aerosol에는 많은 바이러스가 함유되어 있으며 특히 돼지의 경우는 소보다 약 1,000배 정도의 바이러스를 더 많이 배출한다.
본문요약 정보가 도움이 되었나요?

참고문헌 (64)

  1. Grubman, M. J. and Baxt, B. (2004) Foot-and-mouth disease. Clin. Microbiol. Rev. 17, 465-93 

  2. Saiz, M., Nunez, J. I., Jimenez-Clavero, M. A., Baranowski, E. and Sobrino, F. (2002) Foot-and-mouth disease virus: biology and prospects for disease control. Microbes. Infect. 4, 1183-92 

  3. Kitching, R. P. (1998) A recent history of foot-and-mouth disease. J. Compo. Pathol. 118, 89-108 

  4. Leforban, Y. (1999) Prevention measures against foot-and-mouth disease in Europe in recent years. Vaccine 17, 1755-1759 

  5. Fry, E. E., Stuart, D. I. and Rowlands, D. J. (2005) The structure of foot-and-mouth disease virus. Curr. Top. Microbiol. Immunol. 288, 71-101 

  6. McInerney, G. M., King, A. M., Ross-Smith, N. and Belsham, G. J. (2000) Replication-competent foot-and-mouth disease virus RNAs lacking capsid coding sequences. J. Gen. Virol. 81, 1699-1702 

  7. Curry, S., Fry, E., Blakemore, W., Abu-Ghazaleh, R., Jackson, T., King, A., Lea, S., Newman, J. and Stuart, D. (1997) Dissecting the roles of VP0 cleavage and RNA packaging in picornavirus capsid stabilization: the structure of empty capsids of foot-and-mouth disease virus. J. Virol. 71, 9743-9752 

  8. Shieh, J. J., Liang, C. M., Chen, C. Y., Lee, E, Jong, M. H., Lai, S. S. and Liang, S. M. (2001) Enhancement of the immunity to foot-and-mouth disease virus by DNA priming and protein boosting immunization. Vaccine 19, 4002-4010 

  9. Logan, D., Abu-Ghazaleh, R., Blakemore, W., Curry, S., Jackson, T., King, A., Lea, S., Lewis, R., Newman, J., Party, N. and et al. (1993) Structure of a major immunogenic site on foot-and-mouth disease virus. Nature 362, 566-568 

  10. Wong, H. T., Cheng, S. C., Chan, E. W., Sheng, Z. T., Yan, W. Y., Zheng, Z. X. and Xie, Y. (2000) Plasmids encoding foot-and-mouth disease virus VPl epitopes elicited immune responses in mice and swine and protected swine against viral infection. Virology 278, 27-35 

  11. Beard, C., Ward, G, Rieder, E., Chinsangaram, J., Grubman, M. J. and Mason, P. W. (1999) Development of DNA vaccines for foot-and-mouth disease, evaluation of vaccines encoding replicating and non-replicating nucleic acids in swine. J. Biotechnol. 73, 243-249 

  12. Grubman, M. J., Morgan, D. O., Kendall J. and Baxt, B. (1985) Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J. Virol. 56, 120-6 

  13. Donnelly, M. L., Hughes, L. E., Luke, G, Mendoza, H., ten Dam, E., Gani, D. and Ryan, M. D. (2001) The 'cleavage' activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring '2A-like' sequences. J. Gen. Viral. 82, 1027-1041 

  14. Donnelly, M. L., Gani, D., Flint, M., Monaghan, S. and Ryan, M. D. (1997) The cleavage activities of aphthovirus and cardiovirus 2A proteins. J. Gen. Viral. 78, 13-21 

  15. Doedens, J. R. and Kirkegaard, K. (1995) Inhibition of cellular protein secretion by poliovirus proteins 2B and 3A. Embo. J. 14, 894-907 

  16. Brown, C. C., Piccone, M. E., Mason, P. W., McKenna, T. S. and Grubman, M. J. (1996) Pathogenesis of wild-type and leaderless foot-and-mouth disease virus in cattle. J. Viral. 70, 5638-5641 

  17. Jackson, T., Ellard, F. M., Ghazaleh, R. A., Brookes, S. M., Blakemore, W. E., Corteyn, A. H., Stuart, D. I., Newman, J. W. and King, A. M. (1996) Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Viral. 70, 5282-5287 

  18. Yilma, T. (1980) Morphogenesis of vesiculation in foot-and-mouth disease. Am. J. Vet. Res. 41, 1537-1542 

  19. McCullough, K. C., De Simone, F., Brocchi, E., Capucci, L., Crowther, J. R. and Kihm, U. (1992) Protective immune response against foot-and-mouth disease. J. Viral. 66, 1835-1840 

  20. Collen, T. and Doel, T. R. (1990) Heterotypic recognition of foot-and-mouth disease virus by cattle lymphocytes. J. Gen. Viral. 71, Pt 2, 309-315 

  21. Sobrino, F., Saiz, M., Jimenez-Clavero, M. A., Nunez, J. I., Rosas, M. F., Baranowski, E. and Ley, V. (2001) Foot-and-mouth disease virus: a long known virus, but a current threat. Vet. Res. 32, 1-30 

  22. Sanz-Parra, A., Sobrino, F. and Ley, V. (1998) Infection with foot-and-mouth disease virus results in a rapid reduction of MHC class I surface expression. J. Gen. Viral. 79, Pt 3, 433-436 

  23. Alexandersen, S., Zhang, Z., Donaldson, A. I. and Garland, A. J. (2003) The pathogenesis and diagnosis of foot-and-mouth disease. J. Camp. Pathol. 129, 1-36 

  24. Clavijo, A., Wright, P. and Kitching, P. (2004) Developments in diagnostic techniques for differentiating infection from vaccination in foot-and-mouth disease. Vet. J. 167, 9-22 

  25. Mackay, D. K., Bulut, A. N., Rendle, T., Davidson, F. and Ferris, N. P. (2001) A solid-phase competition ELISA for measuring antibody to foot-and-mouth disease virus. J. Viral. Methods. 97, 33-48 

  26. Chenard, G., Miedema, K., Moonen, P., Schrijver, R. S. and Dekker, A. (2003) A solid-phase blocking ELISA for detection of type O foot-and-mouth disease virus antibodies suitable for mass serology. J. Viral. Methods. 107, 89-98 

  27. Reid, S. M., Forsyth, M. A., Hutchings, G. H. and Ferris, N. P. (1998) Comparison of reverse transcription polymerase chain reaction, enzyme linked immunosorbent assay and virus isolation for the routine diagnosis of foot-and-mouth disease. J. Viral. Methods. 70, 213-217 

  28. Chamberlain, J. S., Gibbs, R. A., Ranier, J. E., Nguyen, P. N. and Caskey, C. T. (1988) Deletion screening of the Duchenne muscular dystrophy locus via multiplex DNA amplification. Nucleic. Acids. Res. 16, 11141-11156 

  29. Doel, T. R. (1996) Natural and vaccine-induced immunity to foot and mouth disease: the prospects for improved vaccines. Rev. Sci. Tech. 15, 883-911 

  30. Nair, S. P. and Sen, A. K. (1992) A study on the immune response of sheep to foot and mouth disease virus vaccine type 'O' prepared with different inactivants and adjuvants. Acta. Virol. 36, 473-478 

  31. Ishimaru, D., Sa-Carvalho, D. and Silva, J. L. (2004) Pressure-inactivated FMDV: a potential vaccine. Vaccine 22, 2334-9 

  32. Ward, G, Rieder, E. and Mason, P. W. (1997) Plasmid DNA encoding replicating foot-and-mouth disease virus genomes induces antiviral immune responses in swine. J. Virol. 71, 7442-7447 

  33. Sanz-Parra, A., Vazquez, B., Sobrino, F., Cox, S. J., Ley, V. and Salt, J. S. (1999) Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins. J. Gen. Virol. 80, Pt 3, 671-679 

  34. Aggarwal, N. and Barnett, P. V. (2002) Antigenic sites of foot-and-mouth disease virus (FMDV): an analysis of the specificities of anti-FMDV antibodies after vaccination of naturally susceptible host species. J. Gen. Virol. 83, 775-782 

  35. Li, Y., Aggarwal, N., Takamatsu, H. H., Sterling, C. M., Voyce, C. and Barnett, P. V. (2005) Enhancing immune responses against a plasmid DNA vaccine encoding a FMDV empty capsid from serotype O. Vaccine 

  36. Chinsangaram, J., Beard, C., Mason, P. W., Zellner, M. K., Ward, G. and Grubman, M. J. (1998) Antibody response in mice inoculated with DNA expressing foot-and-mouth disease virus capsid proteins. J. Virol. 72, 4454-4457 

  37. Cedillo-Barron, L., Foster-Cuevas, M., Belsham, G. J., Lefevre, F. and Parkhouse, R. M. (2001) Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J. Gen. Virol. 82, 1713-24 

  38. Zheng, L. Y., Moll, L., Lin, S., Lu, R M. and Luo, E. J. (2005) Enhancing DNA vaccine potency against hantavirus by co-administration of interleukin-12 expression vector as a genetic adjuvant. Chin. Med. J. (Engl). 118, 313-319 

  39. Stratford, R, Douce, G., Bowe, F. and Dougan, G. (2001) A vaccination strategy incorporating DNA priming and mucosal boosting using tetanus toxin fragment C (TetC). Vaccine 20, 516-525 

  40. Chan, E. W., Wong, H. T., Cheng, S. C., Yan, W. Y., Zheng, Z. X, Sheng, Z. T., Zhu, L. Q. and Xie, Y. (2000) An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine. Vaccine 19, 538-546 

  41. Chattergoon, M., Boyer, J. and Weiner, D. B. (1997) Genetic immunization: a new era in vaccines and immune therapeutics. Faseb. J. 11, 753-763 

  42. Moraes, M. P., Mayr, G. A, Mason, P. W. and Grubman, M. J. (2002) Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20, 1631-1639 

  43. Carrillo, C., Wigdorovitz, A., Oliveros, J. C., Zamorano, P. I., Sadir, A. M., Gomez, N., Salinas, J., Escribano, J. M. and Borca, M. V. (1998) Protective immune response to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J. Virol. 72, 1688-1690 

  44. Cedillo-Barron, L., Foster-Cuevas, M., Cook, A., Gutierrez-Castaneda, B., Kollnberger, S., Lefevre, F. and Parkhouse, R. M. (2003) Immunogenicity of plasmids encoding T and B cell epitopes of foot-and-mouth disease virus (FMDV) in swine. Vaccine 21, 4261-4269 

  45. Wigdorovitz, A., Carrillo, C., Dus Santos, M. J., Trono, K., Peralta, A., Gomez, M. C., Rios, R. D., Franzone, P. M., Sadir, A. M., Escribano, J. M. and Borca, M. V. (1999) Induction of a protective antibody response to foot and mouth disease virus in mice following oral or parenteral immunization with alfalfa transgenic plants expressing the viral structural protein VP1. Virology 255, 347-353 

  46. Garcia-Briones, M. M., Blanco, E., Chiva, C., Andreu, D., Ley, V. and Sobrino, F. (2004) Immunogenicity and T cell recognition in swine of foot-and-mouth disease virus polymerase 3D. Virology 322, 264-275 

  47. Rodriguez, L. L., Barrera, J., Kramer, E., Lubroth, J., Brown, F. and Golde, W. T. (2003) A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type-O VP1 and a promiscuous T-helper epitope induces peptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine 21, 3751-3756 

  48. M. J. Francis, G. Z. Hastings, F. Brown, J. Mcdermed, Y. A Lu. and J. P. Tam, (1991) Immunological evaluation of the multiple antigen peptide (Map) system using the major immunogenic site of foot-and-mouth-disease virus. Immunology 73, 249-254 

  49. Murdin, A. D. (1986) Synthetic peptide vaccines against foot and mouth disease. Vaccine 4, 210-211 

  50. Wang, C. Y., Chang, T. Y., Walfield, A. M., Ye, J., Shen, M., Chen, S. P., Li, M. C., Lin, Y. L., Jong, M. H., Yang, P. C., Chyr, N., Kramer, E. and Brown, F. (2002) Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine 20, 2603-2610 

  51. Wang, C. Y., Chang, T. Y., Walfield, A. M., Ye, J., Shen, M., Zhang, M. L., Lubroth, J., Chen, S. P., Li, M. C., Lin, Y. L., Jong, M. H., Yang, P. C., Chyr, N., Kramer, E. and Brown, F. (2001) Synthetic peptide-based vaccine and diagnostic system for effective control of FMD. Biologicals 29, 221-228 

  52. Wang, C. Y. and Walfield, A. M. (2005) Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine 23, 2049-2056 

  53. Wiesmuller, K. H., Jung, G. and Hess, G. (1989) Novel low-molecular-weight synthetic vaccine against foot-and-mouth disease containing a potent B-cell and macrophage activator. Vaccine 7, 29-33 

  54. Beignon, A. S., Brown, F., Eftekhari, P., Kramer, E., Briand, J. P., Muller, S. and Partidos, C. D. (2005) A peptide vaccine administered transcutaneously together with cholera toxin elicits potent neutralising anti-FMDV antibody responses. Vet. Immunol. Immunopathol. 104, 273-280 

  55. Fischer, D., Rood, D., Barrette, R. W., Zuwallack, A., Kramer, E., Brown, F. and Silbart, L. K. (2003) Intranasal immunization of guinea pigs with an immunodominant foot-and-mouth disease virus peptide conjugate induces mucosal and humoral antibodies and protection against challenge. J. Virol. 77, 7486-7491 

  56. Nargi, F., Kramer, E., Mezencio, J., Zamparo, J., Whetstone, C., Van Regenmortel, M. H., Briand, J. P., Muller, S. and Brown, F. (1999) Protection of swine from foot-and-mouth disease with one dose of an all-D retro peptide. Vaccine 17, 2888-2893 

  57. Bittle, J. L., Houghten, R. A., Alexander, H., Shinnick, T. M., Sutcliffe, J. G., Lerner, R A, Rowlands, D. J. and Brown, E (1982) Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence. Nature 298, 30-33 

  58. Brown, F. (1992) New approaches to vaccination against foot-and-mouth disease. Vaccine 10, 1022-1026 

  59. Strohmaier, K., Franze, R. and Adam, K. H. (1982) Location and characterization of the antigenic portion of the FMDV immunizing protein. J. Gen. Virol. 59, 295-306 

  60. Verdaguer, N., Mateu, M. G, Andreu, D., Giralt, E., Domingo, E. and Fita, I. (1995) Structure of the major antigenic loop of foot-and-mouth disease virus complexed with a neutralizing antibody: direct involvement of the Arg-Gly-Asp motif in the interaction. Embo. J. 14, 1690-1696 

  61. Meloen, R. H., Casal, J. I., Dalsgaard, K. and Langeveld, J. P. (1995) Synthetic peptide vaccines: success at last. Vaccine 13, 885-886 

  62. Glass, E. J., Oliver, R. A, Collen, T., Doel, T. R., Dimarchi, R. and Spooner, R. L. (1991) MHC class II restricted recognition of FMDV peptides by bovine T cells. Immunology 74, 594-599 

  63. Taboga, O., Tami, C., Carrillo, E., Nunez, J. I., Rodriguez, A., Saiz, J. C., Blanco, E., Valero, M. L., Roig, X., Camarero, J. A., Andreu, D., Mateu, M. G., Giralt, E., Domingo, E., Sobrino, F. and Palma, E. L. (1997) A large-scale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J. Virol. 71, 2606-2014 

  64. Song, H., Wang, Z., Zheng, D., Fang, W., Li, Y., Liu, Y., Niu, Z. and Qiu, B. (2005) A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine. Biotechnol. Lett. 27, 1669-1674 

저자의 다른 논문 :

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로